WALL, N.J., June 4 /PRNewswire/ -- On April 13, 2009, the Trademark Trial and Appeal Board of the U.S. Patent and Trademark Office granted Vision Pharma, LLC's ("Vision Pharma") motion for judgment on the pleadings and ruled that Vision Pharma's VISRX mark is not confusingly similar to Cornerstone Therapeutics, Inc.'s (Nasdaq: CRTX) ("Cornerstone") ALLERX mark.
In response to Vision Pharma's pending trademark application for the mark VISRX, Cornerstone Biopharma, Inc. initiated an opposition proceeding on the basis that Vision Pharma's VISRX mark is likely to cause confusion with Cornerstone's ALLERX mark. In response, Vision Pharma denied the allegations and asserted counterclaims to cancel Cornerstone's registrations for the ALLERX mark. On April 13, 2009, the Trademark Trial and Appeal Board entered an order ruling that Vision Pharma's VISRX mark is not likely to cause confusion with Cornerstone's ALLERX mark. Sander Busman, President & CEO of Vision Pharma said "We are very pleased with the result."
Vision Pharma and Cornerstone Biopharma, Inc. also are involved in patent litigation pending in the U.S. District Court for the Eastern District of North Carolina. The case is stayed while the patent-in-suit is being reexamined by the U.S. Patent and Trademark Office.
About Vision Pharma
Vision Pharma, a rapidly growing generic pharmaceutical company, specializes in niche items with various delivery options and dosage forms. We provide these quality products at competitive prices while improving the lives of those who take our medicines. Our friendly customer service will act promptly to your requests while continuously improving to fulfill your needs. Maintaining additional inventory ensures our ability to provide increased service levels. The pipeline of generic pharmaceuticals that we plan to market continues to grow at a steady rate. Valuable relationships that are built with our customers show our true dedication to each partnering company. You can count on Vision Pharma to be a recognized leader, now and in the future.
|SOURCE Vision Pharma|
Copyright©2009 PR Newswire.
All rights reserved